3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Thoracic
1
Conditions
Breast Neoplasms
22
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
3
Pancreatic Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Stomach Neoplasms
1
Recurrence
1
Pre-menopausal Breast Cancer
1
Neoplasms
1
Lung Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Fulvestrant
10
Letrozole
4
Alpelisib
4
ribociclib
3
palbociclib
3
Paclitaxel
2
NVP-BKM120
2
volagidemab
1
serabelisib
1
sapanisertib
1
olaparib
1
liposomal doxorubicin
1
gedatolisib
1
exemestane
1
dapagliflozin
1
capivasertib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
Secretin
1
STX-478
1
Metformin
1
Lomustine
1
Leuprolide
1
Irinotecan
1
Imlunestrant
1
Goserelin
1
Gemcitabine
1
Drug Therapy
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
NVP-BKM120
×
Breast
×
Clear all
NCT01633060
2019-01-30
BELLE-3
Novartis
Phase 3
Terminated
432 enrolled
20 charts
NCT01572727
2017-03-09
BELLE-4
Novartis
Phase 2/3
Completed
416 enrolled
11 charts